Guided Therapeutics (GTHP) Other Non-Current Liabilities (2013 - 2025)

Guided Therapeutics has disclosed Other Non-Current Liabilities across 12 years of filings, most recently posting $37000.0 for Q4 2025.

• Other Non-Current Liabilities for Q4 2025 came in at $37000.0, down 68.64% year-over-year; the trailing twelve-month figure through Dec 2025 was $37000.0 (down 68.64% YoY), and the FY2025 annual result was $37000.0, down 68.64% from the prior year.
• Other Non-Current Liabilities came in at $37000.0 for Q4 2025 at Guided Therapeutics, down from $79000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $118000.0 in Q4 2024 to a low of -$38000.0 in Q3 2021.
• The 4-year median for Other Non-Current Liabilities is $26000.0 (2021), against an average of $29416.7.
• Across the five-year window, Other Non-Current Liabilities plunged 115.62% in 2022 and surged 361.54% in 2025, its largest moves.
• Guided Therapeutics' Other Non-Current Liabilities stood at $32000.0 in 2021, then slumped by 115.62% to -$5000.0 in 2022, then jumped by 2460.0% to $118000.0 in 2024, then slumped by 68.64% to $37000.0 in 2025.
• The last three Other Non-Current Liabilities figures came in at $37000.0 (Q4 2025), $79000.0 (Q3 2025), and $60000.0 (Q2 2025), per Business Quant data.